Administration of Opdivo (nivolumab) before surgical resection in patients with glioblastoma appeared safe and feasible, according to phase 2 trial results published in Nature Medicine. Administration ...

Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...

Opdivo is the first and only PD-1 inhibitor to demonstrate superior overall survival versus docetaxel in non-squamous non-small cell lung cancer, with an 18-month overall survival rate of 39% Longer ...

Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection ...

SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, announced today the first patient ...

Bristol Myers Squibb today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary ...

The U.K.’s drug cost watchdog has endorsed Bristol Myers Squibb’s Opdivo to treat certain bladder cancer patients, though the recommendation is couched by several caveats. The National Institute for ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced promising phase 2 results for CABOMETYX ® (cabozantinib) in combination with Bristol Myers Squibb’s OPDIVO ® (nivolumab) ...

Opdivo is a programmed death receptor-1 (PD-1) blocking antibody. The Food and Drug Administration (FDA) has expanded the approval of Opdivo ® (nivolumab) to include adjuvant treatment of patients 12 ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX ® (cabozantinib) in ...

On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...